New technology helps prevent oral mucositis for head and neck cancer patients undergoing radiation or chemoradiation
Fort Myers, Fla. & Bethesda, Md., March 08, 2021 (GLOBE NEWSWIRE) — The Center for Cancer and Blood Disorders (CCBD), an American Oncology Network (AON) partner, is pleased to announce it is now offering THOR® Photobiomodulation (PBM) therapy for the prevention and treatment of mouth sores in cancer therapy patients. Patients can now receive light therapy at both office locations in Maryland, Bethesda at 6410 Rockledge Drive, Suite 660 and in Germantown at 19735 Germantown Road, Suite 255.
The positive effects of PBM therapy on oral mucositis have been reported in 42 randomized controlled trials and nine systematic reviews, reducing the incidence of severe mucositis. Guidelines issued by the Multinational Association of Supportive Care in Cancer (MASCC) in 2019 recommend the use of PBM for the prevention and treatment of oral mucositis caused by radiation.
“Cancer patients deal with many side effects when they go through treatment,” said Dr. Mark G. Goldstein of The Center for Cancer and Blood Disorders. “Head and neck cancer patients receiving a high dose of chemoradiation treatment are almost 100 percent guaranteed to get a high level of oral mucositis. These painful mouth sores can make everyday tasks like eating, swallowing or brushing teeth difficult. Being able to offer our patients light therapy can bring therapeutic benefit. Without sores, patients can maintain their treatment schedules and may be able to avoid feeding tubes as well as narcotics. Maintaining treatment schedules can improve cancer control and overall outcome, along with reducing any long-term side effects.”
Each light treatment takes about 60 seconds and is painless. The light unit is shaped like a flat popsicle which is placed inside the mouth. With this single light unit, the entire mouth can be treated including the tongue as well as the areas near and behind the tonsils. Research done in the United States, United Kingdom, Brazil, India and Europe, shows no side effects.
Medical Director and CEO of The Center for Cancer and Blood Disorders Dr. Ralph Boccia added, “New developments continue to improve a patient’s quality of life. Currently only a handful of medical universities offer this light therapy. We’re excited to be one of the first community medical oncology practices in the country to be able to offer and treat mucositis, a major side effect suffered by many cancer patients undergoing chemotherapy treatment.”
AON CEO Brad Prechtl, MBA said, “Bringing the most advanced and innovative technologies to patients is an essential part of CCBD’s mission as a community oncology practice to provide exceptional cancer care to patients close to home.”
AON is an alliance of physicians and seasoned healthcare leaders that provides a unique array of enhanced services to its affiliated community-based oncology practices. It consistently strives to find innovative ways to connect with patients. AON’s community oncology model allows physicians to focus on what matters most — their patients.
About The Center for Cancer and Blood Disorders: (CCBDMD.com)
Specialists in the diagnosis and treatment of blood disorders and cancer, The Center for Cancer and Blood Disorders has been serving patients in the communities and surrounding areas of Bethesda and Germantown, Maryland for more than 25 years. Their individualized approach to patient care includes chemotherapy, targeted therapy, immunotherapy and when appropriate, cutting edge therapies on clinical trials. The practice regularly performs more than 300 clinical trials on new and developing diagnostic devices and techniques for cancer and diseases. Patients receive home delivery of oral cancer medications, in-house lab and pathology and on-site infusion therapy. The practice also offers comprehensive support with nutrition guidance and financial counseling.
About American Oncology Network, LLC: (AONcology.com)
American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 92 physicians and 62 nurse practitioners and physician assistants practicing across 16 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most – providing the highest quality care for patients.
The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.
AON also provides a unique model of physician led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences will be at the very pinnacle of cancer care today.
News source: globenewswire.com